^
    Apply
    211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCI-2018-01788) (NCT03670966)
    Phase 1/2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    07/10/2019
    Primary completion :
    06/28/2027
    Completion :
    03/20/2029
    HLA-DRB1 • HLA-B
    |
    cyclophosphamide • sirolimus • fludarabine IV • Iomab-B (I-131-apamistamab) • cyclophosphamide intravenous
    Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (MED20-165) (NCT04512716)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    03/08/2024
    Initiation :
    02/02/2021
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    CD20 • CD19
    |
    CD19 expression
    |
    Iomab-B (I-131-apamistamab) • apamistamab-I-131 (Iomab-ACT) • vadacabtagene leraleucel (JCAR015)
    Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) (NCT02665065)
    Phase 3
    Actinium Pharmaceuticals
    Active, not recruiting
    Last update posted :
    07/19/2023
    Initiation :
    06/01/2016
    Primary completion :
    06/01/2022
    Completion :
    12/01/2026
    HLA-DRB1 • PTPRC • HLA-B • HLA-C
    |
    PTPRC expression
    |
    carboplatin • cytarabine • doxorubicin hydrochloride • azacitidine • cyclophosphamide • Iomab-B (I-131-apamistamab)